The fifth round of national procurement of these pharmaceutical companies to enter

The fifth batch of national procurement, the competitive landscape continues to change, and many pharmaceutical companies enter the game

A number of pharmaceutical companies entered the fifth batch of national procurement

According to Cyber ​​Blue, since May 8th, the Shanghai Sunshine Pharmaceutical Purchasing Network officially issued a notice stating that the Joint Purchasing Office will carry out the fifth batch of state-organized centralized drug procurement related information declaration work, and a number of pharmaceutical companies have entered the fifth batch.

According to earlier statistics from the Insight database, after the fifth batch of national procurement reports began on April 19, as of May 6, another 18 products have been reviewed and competition has intensified.

According to Cyber ​​Blue, since May 8th, there have been about 10 fifth batches of nationally sourced varieties that have been reviewed by enterprises.

On May 14th, the State Food and Drug Administration issued the drug approval documents.

They are Ganciclovir for injection (50mg, 250mg) from Wuhan Pusheng, iodixanol injection from Beijing Beilu, rivaroxaban tablets from Broad Pharmaceutical, and budesonide suspension from Changfeng Pharmaceutical for inhalation Solution, Jiangsu Kefeiping's rivaroxaban tablets, Renheyikang's ipratropium bromide solution for inhalation.

As of May 14th, Rivaroxaban has been evaluated by 17 pharmaceutical companies including Yangzijiang Pharmaceutical, CSPC Ouyi, Huahai Pharmaceutical, Jiangsu Kefeiping and Broad Pharmaceutical;

Iodixanol injection meets the fifth batch of national procurement bidding qualifications.

Four companies including Zhengda Tianqing, Jiankangyuan, Sichuan Prime, and Changfeng Pharmaceutical for budesonide suspension for inhalation have entered a new round of centralized procurement list;

The bidding pharmaceutical companies for ipratropium bromide solution for inhalation include two importers Boehringer Ingelheim and Unitel Pharmaceuticals, plus four domestic pharmaceutical companies that have been reviewed-Shantou Medical, Health Yuan Pharmaceutical, Sichuan Prime and Renhe Yikang;

The latest competition pattern for ganciclovir for injection is "1+3"-the original research pharmaceutical company Roche + three domestic pharmaceutical companies Yangzijiang Pharmaceutical, Hainan Puli, and Wuhan Pusheng.

It is worth noting that, according to the Insight database, the online price of the budesonide suspension of Zhengda Tianqing in March is 12.

5 large varieties of injections have been reviewed by enterprises

On May 10, the State Food and Drug Administration issued a new batch of approval documents, of which 5 of the fifth batch of nationally sourced varieties have been reviewed by enterprises, all of which are injections-namely: Hengrui Medicine's iodixanol injection and Osaikang Docetaxel injection, Hongri Pharmaceutical’s Fasudil Hydrochloride Injection, Zhengda Tianqing’s Palonosetron Hydrochloride Injection, and Qilu Pharmaceutical’s Decitabine for Injection.

Data show that docetaxel injection has been reviewed by 7 pharmaceutical companies, namely Chia Tai Tianqing, Yangtze River Pharmaceutical, Sichuan Huiyu Pharmaceutical, Jiangsu Hengrui, Qilu Pharmaceutical, Sichuan Meida Kangjiale Pharmaceutical, and Osai Kang .

As for Palonosetron, it is the first-line medication to prevent nausea and vomiting caused by chemotherapy and postoperative nausea and vomiting.

Decitabine for injection is used for the chemotherapy of myelodysplastic syndrome (MDS) and elderly leukemia.

Data shows that the current market for decitabine for injection is mainly occupied by Hausen and Chia Tai Tianqing.

According to incomplete statistics, up to now, Qilu Pharmaceutical has 11 over-evaluated products that have entered the fifth batch of national procurement-including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, and saxaglipta Tine tablets, fasudil hydrochloride injection, palonosetron hydrochloride injection, ceftriaxone sodium for injection, ceftazidime for injection, gemcitabine hydrochloride for injection, decitabine hydrochloride for injection, and ropivacaine hydrochloride injection.

The injection market may welcome a new round of shock

In the fifth round of national procurement, 60 varieties, 202 specifications, and 30 injections were included, making it the largest number ever-antibiotics cefuroxime injection, ceftriaxone injection, ceftazidime injection, ceftazolin injection, and digestive products Esomeprazole (esomeprazole) injection, anti-tumor drug docetaxel injection, anesthetic drug ropivacaine injection and other injections are all included.

Some analysis pointed out that compared with the first four batches involving 3, 1, 3, and 8 injections, the fifth round of national procurement will have a big impact on the injection market.

The fifth batch of 30 injections over-evaluation status and market leading companies

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

Note: The red mark of TOP1 companies has been evaluated, and the statistics are as of May 17

According to data from Menet.
com, in 2019, the sales of terminal chemical injections in urban public hospitals, county-level public hospitals, urban community centers and township health centers in China exceeded 600 billion, which is much higher than the share of oral preparations.

According to the statistics of Minenet, among the 30 injections involved in the fifth batch, 11 products are still leading the market by imported brands, including fluconazole sodium chloride injection, ropivacaine injection, levofloxacin sodium chloride injection, Oxaliplatin injection, etc.

In addition, 12 companies with the largest market share of injections have been reviewed-such as Hengrui's cisatracurium benzenesulfonate injections, iodixanol injections, and docetaxel injections; and Hausen's gemcitabine Injection, decitabine injection; iohexol injection from Yangtze River, bendamustine hydrochloride for injection from Zhengda Tianqing Pharmaceutical Group, etc.

It is expected that before the official opening of the fifth batch of national procurement, a number of pharmaceutical companies will enter the market.
As for the competition in the field of injections, due to its high dependence on the hospital market, the situation may still be fierce.